Jean-Paul  Kress net worth and biography

Jean-Paul Kress Biography and Net Worth

Chairman of Management Board of MorphoSys

As a trained physician, Jean-Paul Kress has devoted his career to bringing transformative medicines to patients. Since joining MorphoSys as CEO in September 2019, he has strategically repositioned the company from a leading antibody technology provider to a global, commercial-stage biopharmaceutical company with a strong late-stage pipeline. As part of this evolution, the company launched its first medicine in the U.S. – an immunotherapy for an aggressive form of blood cancer – and significantly enriched its pipeline through the acquisition of Constellation Pharmaceuticals in 2021. In addition to his work at MorphoSys, Jean-Paul serves as Chair of the Board of Directors at ERYTECH Pharma.

Prior to MorphoSys, Jean-Paul was CEO of Syntimmune where he oversaw the company’s transformation to a late-stage development immunology company, resulting in its acquisition by Alexion. He held several senior leadership roles at pharmaceutical companies, including EVP, President of International and Head of Global Therapeutic Operations at Biogen, and SVP, Head of North America at Sanofi Genzyme, where he was instrumental in launching Dupilumab, the first biologic agent approved in atopic dermatitis. Previously, he was President and Chief Executive Officer of Sanofi Pasteur MSD and held leadership positions at Gilead, AbbVie and Eli Lilly and Company. He also served on Sarepta Therapeutics’ Board of Directors.

Jean-Paul received an M.D. degree from Faculté Necker-Enfants Malades in Paris, and graduate and post-graduate degrees in biochemistry and in molecular and cellular pharmacology from Ecole Normale Supérieure in Paris.

How old is Jean-Paul Kress?

Dr. Kress is currently 59 years old. There are 2 older executives and no younger executives at MorphoSys. Learn More on Jean-Paul Kress' age.

How do I contact Jean-Paul Kress?

The corporate mailing address for Dr. Kress and other MorphoSys executives is SEMMELWEISSTR. 7, PLANEGG 2M, 82152. MorphoSys can also be reached via phone at (498) 989-9270 and via email at [email protected]. Learn More on Jean-Paul Kress' contact information.

Has Jean-Paul Kress been buying or selling shares of MorphoSys?

Jean-Paul Kress has not been actively trading shares of MorphoSys in the last ninety days. Learn More on Jean-Paul Kress' trading history.

Who are MorphoSys' active insiders?

MorphoSys' insider roster includes Jean-Paul Kress (Chairman of Management Board), and Sung Lee (CFO & Member of Management Board ). Learn More on MorphoSys' active insiders.

Jean-Paul Kress Insider Trading History at MorphoSys

See Full Table

Jean-Paul Kress Buying and Selling Activity at MorphoSys

This chart shows Dr. Jean-Paul Kress's buying and selling at MorphoSys by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

MorphoSys Company Overview

MorphoSys logo
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.
Read More

Today's Range

Now: $18.14
Low: $18.10
High: $18.16

50 Day Range

MA: $16.07
Low: $9.12
High: $18.18

2 Week Range

Now: $18.14
Low: $3.89
High: $18.31

Volume

279,759 shs

Average Volume

367,005 shs

Market Capitalization

$2.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16